Jan 21, 2020

Nivolumab transforms practice for advanced, refractory nonsquamous NSCLC | MDedge Hematology and Oncology

Key clinical point: Nivolumab provided superior overall survival vs. docetaxel and should be considered the new standard of care for previously treated nonsquamous NSCLC. Major finding: The median overall survival was 12.2 months with nivolumab vs.

Proceed to the page: http://linkis.com/2PgN6

Similar Articles Added Earlier

Similar Articles Added Today

Most Recent mdedge.com Articles

Latest Links Processed